Amivas (US), LLC Announces U.S. Launch of Artesunate for Injection for Initial Treatment of Severe Malaria
Artesunate for Injection is available for order via:
- Artesunate for Injection is available for order via:
Indicated for the initial treatment of severe malaria in adult and pediatric patients, Artesunate for Injection received marketing approval by the U.S. Food and Drug Administration (FDA) on May 26, 2020. - Artesunate for Injection is the first FDA-approved product that Amivas, headquartered in Frederick, Maryland, has introduced to its commercial portfolio.
- Hospitals may now stock Amivas' Artesunate for Injection for immediate treatment of patients with severe malaria to prevent poor outcomes such as death.
- Pediatric Use: The safety and effectiveness of Artesunate for Injection for the treatment of severe malaria have been established in pediatric patients.